61 articles - From Friday Sep 19 2025 to Friday Sep 26 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| J Crohns Colitis |
|---|
meta-analyses and systematic reviews
| Am J Clin Nutr |
|---|
The effects of whole foods and dietary patterns on flow mediated dilation: a systematic review and meta-analysis of randomized controlled trials. The systematic review provides evidence that fruits, vegetables, soy, nuts and seeds, cocoa and tea, as well as following a Mediterranean diet are the most effective dietary strategies for improving endothelial function as measured by FMD. However, findings should be interpreted with caution due to moderate to low certainty of evidence and some concerns or high risk of bias in many cases. |
| Inflamm Bowel Dis |
Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-Analysis. Anti-tumor necrosis factor agents, namely ADA and IFX, are the most effective treatments in reducing postoperative recurrence of CD, followed by VDZ. THPs and antibiotics ranked lower than biologics. Nonpharmacological interventions such as curcumin, vitamin D, and probiotics did not demonstrate efficacy in reducing postoperative recurrence. |
Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies. The mycobiome is altered in IBD, as differences in beta diversity were found between cases and controls consistently. Future studies should carefully standardize every step from sample collection through analysis and data processing, allowing external validation of findings. Inclusion of treatment naïve patients and symptomatic controls could further advance this field. |
Immunomodulators and Advanced Therapies for Induction of Remission in Crohn's Disease: A Systematic Review and Network Meta-Analysis. Combination of anti-tumor necrosis factors (anti-TNFs) and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for the induction of clinical remission. More novel therapies appear to have similar effect sizes but with increased imprecision of the estimates. |
Systematic Review of Available Intestinal Ultrasound Scores for Inflammatory Bowel Disease and Update on Validation Studies. IUS scoring systems are easy-to-use tools for standardizing communication among sonographers. Recent validation studies for a few scores have confirmed their applicability to daily IBD practice. |
| J Crohns Colitis |
Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort study. Only a few of the variables suggested to predict response to anti-TNF showed acceptable performance in pediatric CD, mainly those that included post-induction indicators. These findings highlight the limited generalizability of existing predictors and the importance of external validation before clinical implementation of prediction rules. |
| Pancreatology |
Early versus delayed removal of lumen apposing metal stent after cystogastrostomy: a systematic review and meta-analysis. Delayed removal of LAMS even beyond 4 weeks may not be associated with an increased risk of complications. The timing of removal should be guided by radiologic and clinical responses. |
RCT, clinical trials, retrospective studies, etc…
| Am J Clin Nutr |
|---|
Associations between serum bile acid profile and mortality in patients with coronary artery disease: a cohort study. Our findings suggest that higher serum levels of unconjugated bile acids, specifically CA, CDCA, DCA and HDCA levels, are significantly associated with lower cardiovascular and all-cause mortality risks in CAD patients. |
Environmental impact, nutritional adequacy, and monetary cost of current vs. healthy and sustainable diets in Mexico: modelling study. All HSDs had lower cost and environmental impact compared to the current Mexican diet. Despite some nutrient inadequacies, they offer a feasible foundation to guide sustainable public health nutrition strategies in Mexico. |
Microbiome-related metabolites in early to mid-pregnancy and risk of fetal growth extremes: A metabolome-wide association study. We identified common and unique microbiome-related metabolites associated with risk of fetal growth extremes. Given that microbiota is malleable, our findings may inform strategies to optimize intrauterine microbial-metabolic profile and fetal growth. Clinical trial registry number Not available due to the observational nature of the study. |
Relationship between skeletal muscle indicators and clinical outcomes in cystic fibrosis is modified by adiposity and CFTR modulator use: A cross-sectional analysis. PwCF exhibited lower muscle mass, strength, and quality than controls, with muscle function linked to glucose tolerance. Lung function relationships with muscle mass differed by CFTR modulator use, while excess adiposity attenuated strength-related functional benefits. This study highlights the need for personalized approaches to CF management. |
Spot urine sampling yields reliable measurements for urine caffeine and caffeine metabolites over short to intermediate timeframes in a regional cohort of 50 US adults. 1 to 2 spot urine samples were sufficient to obtain a reliable concentration estimate (ICC ≥ 0.80) for caffeine and most caffeine metabolites during 24-h or 1-week sampling timeframes with appropriate urine flow adjustment, with 2 to 3 spot urine samples being sufficient for sampling over 6 weeks. |
The effects of consumption of interesterified fats rich in palmitic acid versus stearic acid on intermediary markers of cardiometabolic disease risk: a randomized controlled trial in healthy adults. Commercially relevant 16 0-rich IE fats consumed at 10% energy for a 6-week period do not adversely affect total HDL cholesterol ratio or other CMD risk markers compared with 18 0-rich fats. Long-term effects could not be determined from this trial. Clinical trial registry number NCT04418102. |
| Inflamm Bowel Dis |
Cognitive Behavioral Therapy for Insomnia May Improve Sleep and Pain in Crohn's Disease: A Waitlist Control Pilot Trial. The results highlight the importance of addressing sleep concerns in inflammatory bowel disease, particularly in people with persistent pain or fatigue. Future trials powered to detect changes in pain and inflammation are warranted. |
Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis. Fecal calprotectin correlates with endoscopic and histologic disease activity and can be used as a surrogate marker for disease activity. Our study prospectively demonstrated optimal cutoff values to discriminate histoendoscopic remission. |
Distinct Retrotransposon Transcriptome in Pediatric Crohn's Disease. Retrotransposon transcriptome in children with CD significantly differed from non-IBD controls in ileal biopsies with 15 retrotransposon loci consistently downregulated in CD. The possible regulatory function of these retrotransposon loci merits additional research. This study may provide valuable perspectives for the advancement of novel therapeutic strategies. |
Factors Associated with Fistulizing Crohn's Disease in Children at Diagnosis: A Cross-Sectional Study. This study emphasizes the importance of performing perianal MRI early at the diagnosis as occult perianal fistulizing Crohn's disease may be discovered. Male sex, granulomas on intestinal biopsies and anal fissures were associated both with the presence of PFCD and increased severity. |
Genome-Wide Aggregated Trans-Effects Analysis Implicates Deficient Type III Interferon Signaling as a Key Cause of Inflammatory Bowel Disease. These results implicate down-regulation of Type III interferon signaling as a core pathway in the etiology of inflammatory bowel disease, supported by reports of monogenic inflammatory bowel disease caused by rare loss-of-function variants and by perturbation in experimental models of colitis. Deficient Type III interferon signaling may be amenable to therapeutic intervention. |
Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study. Older adults are more likely to develop ADAs against TNFi compared to younger adults. Proactive TDM may be considered in this population for early identification of ADAs and subtherapeutic trough levels, enabling timely dose escalation or treatment modification. |
Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges. Intestinal ultrasonography is increasingly being integrated into clinical trials to assess transmural inflammatory changes in CD, with IUS-based measures of transmural remission or response showing promise as potential endpoints. Although its advantages are clear, addressing these unmet needs is essential to broaden the adoption of IUS in both clinical trials and routine clinical practice. |
Metagenomic Sequencing Reveals Distinct Gut Microbiome Profiles in Therapy-Naïve de Novo Pediatric Inflammatory Bowel Disease. We observed profound gut microbiome differences between de novo, therapy-naïve pediatric IBD patients and controls. While microbiome profiles hold promise for improving diagnostic precision, their predictive value for therapy response seems limited. |
Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series. This case series describes striking clinical and radiological responses in 3 Crohn's disease patients with persistent perineal complications following proctectomy treated with upadacitinib. It highlights the potential of advanced therapies for this refractory inflammatory bowel disease phenotype with limited treatment options. |
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease. Although the primary endpoint of clinical response was not met at Week 16, ustekinumab IV reinduction showed numerical improvements in objective endpoints including inflammatory biomarkers and endoscopic outcomes compared with SC maintenance therapy. Safety and immunogenicity results were consistent with the established profile of ustekinumab. |
| J Crohns Colitis |
Examining the role of faecal microbiota transplantation for inducing remission in resistant ulcerative proctitis and distal ulcerative colitis (up-FMT). Antibiotic conditioning followed by FMT enema therapy was well tolerated and demonstrated efficacy in inducing clinical remission in UP. Further controlled studies of FMT in UP are warranted alongside mechanistic assessment of both faecal and mucosa-associated microbiome. |
Glucagon-Like Peptide (GLP-1) Receptor Agonists in Inflammatory Bowel Disease: Mechanisms, Clinical Implications, and Therapeutic Potential. Their impact on drug absorption, safety in gastrointestinal disease, and interactions with existing inflammatory bowel disease therapies require further exploration. This review synthesises the mechanistic rationale, pre-clinical evidence, and clinical data to date, highlighting the potential utility and safety considerations of glucagon-like peptide-1 receptor agonists in inflammatory bowel disease and emphasises the need for robust prospective trials to ascertain their safety and efficacy in this patient population. |
Implementation of Values based healthcare in inflammatory bowel disease-a review article. In addition, we outline key enablers and barriers to implementation of VBHC models in IBD. We then describe the ideal composition of IBD VBHC models and parameters required for implementation and demonstration of their value proposition. |
Mucosal Kinase Activity and Inflammatory Profiles in Inflammatory Bowel Disease, and in Relation with Tofacitinib Response. Mucosal kinase activity profiles are associated with inflammation in IBD, with distinct differences between UC and CD. Baseline kinase activity appears to predict response to tofacitinib, with a marked reduction in kinase activity observed after 8 weeks of treatment in responders. These findings highlight the potential of kinase activity profiling in optimizing therapeutic strategies for IBD. |
Real-Life Durability and Risk Factors for Biologic Discontinuation in Pediatric Inflammatory Bowel Disease: Results from the Sigenp IBD Registry. Biologic persistence varied by disease type and biologic agent. TDM was associated with longer treatment durability, while combination therapy had a limited effect. Further prospective studies are needed to refine biologics optimization strategies in pediatric IBD. |
| Liver Transpl |
Early liver transplantation in Alcohol-Associated liver disease - evolution of practice, patient selection, management & outcomes. Notably, racial, ethnic and geographic disparities in access to eLT for ALD have emerged, highlighting the need for more standardized and equitable practices. This review traces the development and expansion of eLT in ALD, addressing selection and management challenges, while proposing a biopsychosocial framework to optimize patient and graft outcomes across the liver transplantation continuum. |
HCV NAT+ consent improves liver transplant and waitlist mortality in patients listed for HCC MELD exceptions. HCV NAT+ listing has increased in HCC MELD exception patients, and listing is associated with increased transplantation and reduced mortality. Given substantial center-level variability in NAT+ listing, standardized efforts are needed to improve patient education and access to HCV NAT+ organs. |
Incidence and risk factors for portal vein complications after pediatric liver transplantation: A retrospective cohort analysis from the PORTAL registry. The highest rates of PVS and the lowest rates of PVO were observed in high-volume centers. These findings clarify the incidence of PVCs among pLT recipients and provide critical insights to improve prevention, early detection, and management strategies for these complications. |
Liver transplantation in well-selected patients with unresectable colorectal liver metastases. Liver transplantation for patients with unresectable colorectal liver metastases leads to a significant survival advantage compared to chemotherapy alone. Living-donor liver transplantation is a suitable and safe method to expand organ availability for selected patients. |
| Pancreas |
Alternative Splicing of Secretin Receptor (SCTR) and its low Expression Drive the Occurrence of Pancreatic Ductal Adenocarcinoma. This study provides novel insights into identifying potential therapeutic targets for pancreatic cancer, highlighting that SCTR may serve as a promising prognostic and diagnostic biomarker, with its low expression significantly associated with poor clinical outcomes in PDAC. |
| Pancreatology |
An explainable prediction model for lymphovascular invasion and its prognostic value in resected pancreatic ductal Adenocarcinoma:A two-center study. The explainable LightGBM model is an effective, non-invasive, and visualizable computer-aided tool for predicting the LVI status in patients with PDAC. |
Diagnostic accuracy and Patient Derived Organoid (PDO) yield of 19G vs 22G Franseen needles for EUS-Guided biopsy in solid pancreatic lesions: A prospective comparative study. Compared to 22G, the 19G- FNB needle did not provide higher diagnostic accuracy or PDO yield, suggesting no need for larger needle sizes for PDO generation. |
Impact of Textbook Oncologic Outcome on long term survival after resection for pancreatic adenocarcinoma. TOO could be achieved in one third of pancreatic resections for PDAC but in this series was not associated with improved long-term outcomes. TOO remains a good surgical quality metric but not a prognostic marker. |
Performance of the EndPAC risk score for pancreatic cancer in new onset diabetes patients with missing data - a database study in the British population. Use of imputation methods enabled us to use the EndPAC score for al NOD patients. However, use of the EndPAC score alone is still not sufficient to select NOD patients for diagnostic workup, with or without complete information. Its use in combination with a biomarker might lead to a better risk-benefit ratio. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Inflamm Bowel Dis |
|---|
| J Crohns Colitis |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Inflamm Bowel Dis |
|---|
| J Crohns Colitis |
| Liver Transpl |
Letters to the editors and authors’ replies
| Pancreatology |
|---|